Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | SLC22A12 | Q96S37 | 11/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.49 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.49 |
| ▸ | SLC22A8 | Q8TCC7 | 2/20 | 0.49 |
| ▸ | SLC22A11 | Q9NSA0 | 2/20 | 0.49 |
| ▸ | ALKBH2 | Q6NS38 | 1/20 | 0.48 |
| ▸ | ALKBH3 | Q96Q83 | 1/20 | 0.48 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.48 |
| ▸ | PTGES | O14684 | 1/20 | 0.47 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | KDM1A | O60341 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30560893 | 1.00 | MEN1 (0.56) | MEN1ALDH1A1KMT2ASLC22A12CYP2C9 | |
| SCHEMBL30560821 | 0.81 | KDM4E (0.43) | KMT2A | |
| SCHEMBL30560873 | 0.81 | ALDH1A1 (0.47) | ALDH1A1SLC40A1KDM1A | |
| SCHEMBL16296153 | 0.81 | KDM4E (0.43) | KMT2A | |
| SCHEMBL16296178 | 0.81 | ALDH1A1 (0.47) | ALDH1A1SLC40A1KDM1A | |
| SCHEMBL16295537 | 0.80 | HTR6 (0.46) | MEN1ALDH1A1KMT2ACYP2C9 | |
| SCHEMBL16295113 | 0.80 | HSD17B13 (0.42) | MEN1ALDH1A1KMT2APTGES | |
| SCHEMBL30560843 | 0.80 | HSD17B13 (0.42) | MEN1ALDH1A1KMT2APTGES | |
| SCHEMBL18065846 | 0.80 | KDM4E (0.49) | — | |
| SCHEMBL16295799 | 0.78 | KMT2A (0.49) | MEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3008045-B1 | ANTIBACTERIAL THIAZOLECARBOXYLIC ACIDS | ANTABIO SAS (FR) | 2018-05-09 | — | — | EP | claimed |
| US-9914712-B2 | Antibacterial thiazolecarboxylic acids | ANTABIO SAS (FR) | 2018-03-13 | — | — | US | claimed |
| US-20160272601-A1 | Antibacterial Thiazolecarboxylic Acids | ANTABIO SAS (FR) | 2016-09-22 | — | — | US | claimed |
| EP-3008045-A1 | ANTIBACTERIAL THIAZOLECARBOXYLIC ACIDS | Antabio SAS (FR) | 2016-04-20 | — | — | EP | claimed |
| WO-2014198849-A1 | ANTIBACTERIAL THIAZOLECARBOXYLIC ACIDS | ANTABIO SAS (FR) | 2014-12-18 | — | — | WO | claimed |
| US-12378244-B2 | Diazabicyclooctanones as inhibitors of serine β-lactamases | ANTABIO SAS (FR) | 2025-08-05 | — | — | US | disclosed |
| US-20240391919-A1 | DIAZABICYCLOOCTANONES AS INHIBITORS OF SERINE BETA-LACTAMASES | ANTABIO SAS (FR) | 2024-11-28 | — | — | US | disclosed |
| US-11905286-B2 | Diazabicyclooctanones as inhibitors of serine beta-lactamases | ANTABIO SAS (FR) | 2024-02-20 | — | — | US | disclosed |
| CN-117384155-A | Diazabicyclooctanones as serine beta-lactamase inhibitors | 安塔比奥公司 | 2024-01-12 | — | — | CN | disclosed |
| EP-4272831-A2 | DIAZABICYCLOOCTANONES AS INHIBITORS OF SERINE BETA-LACTAMASES | Antabio SAS (FR) | 2023-11-08 | — | — | EP | disclosed |
| CN-111954671-B | Diazabicyclooctanones as serine beta-lactamase inhibitors | 安塔比奥公司 | 2023-09-01 | — | — | CN | disclosed |
| EP-3833665-B1 | DIAZABICYCLOOCTANONES AS INHIBITORS OF SERINE BETA-LACTAMASES | ANTABIO SAS (FR) | 2023-07-19 | — | — | EP | disclosed |
| EP-3833665-A1 | DIAZABICYCLOOCTANONES AS INHIBITORS OF SERINE BETA-LACTAMASES | Antabio SAS (FR) | 2021-06-16 | — | — | EP | disclosed |
| CN-111954671-A | Diazabicyclooctanones as serine beta-lactamase inhibitors | 安塔比奥公司 | 2020-11-17 | — | — | CN | disclosed |
| WO-2020030761-A1 | DIAZABICYCLOOCTANONES AS INHIBITORS OF SERINE BETA-LACTAMASES | ANTABIO SAS (FR) | 2020-02-13 | — | — | WO | disclosed |
| EP-3008045-B1 | ANTIBACTERIAL THIAZOLECARBOXYLIC ACIDS | ANTABIO SAS (FR) | 2018-05-09 | — | — | EP | disclosed |
| US-9914712-B2 | Antibacterial thiazolecarboxylic acids | ANTABIO SAS (FR) | 2018-03-13 | — | — | US | disclosed |
| US-20160272601-A1 | Antibacterial Thiazolecarboxylic Acids | ANTABIO SAS (FR) | 2016-09-22 | — | — | US | disclosed |
| EP-3008045-A1 | ANTIBACTERIAL THIAZOLECARBOXYLIC ACIDS | Antabio SAS (FR) | 2016-04-20 | — | — | EP | disclosed |
| WO-2014198849-A1 | ANTIBACTERIAL THIAZOLECARBOXYLIC ACIDS | ANTABIO SAS (FR) | 2014-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11905286-B2 | Diazabicyclooctanones as inhibitors of serine beta-lactamases | STS, BCKDK, PEPD | MEN1 2328/4885ALDH1A1 650/4885KMT2A 2345/4885 |
| US-20240391919-A1 | DIAZABICYCLOOCTANONES AS INHIBITORS OF SERINE BETA-LACTAMASES | STS, BCKDK, PEPD | MEN1 2328/4885ALDH1A1 650/4885KMT2A 2345/4885 |
| US-12378244-B2 | Diazabicyclooctanones as inhibitors of serine β-lactamases | STS, PEPD, BCKDK | MEN1 2378/4885ALDH1A1 669/4885KMT2A 2170/4885 |
| US-20160272601-A1 | Antibacterial Thiazolecarboxylic Acids | ME1, TALDO1, COASY | MEN1 1657/4885ALDH1A1 40/4885KMT2A 1824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.